Tulane University

Running trials

• Not yet recruiting

  Modality Choice Before and After Failure for the Treatment of Painful Diabetic Neuropathy

  NCT07795593· Phase 4· Source

• Recruiting

  Combatting HIV Or Other STIs Early (CHOOSE)

  NCT07510048· Source

• Recruiting

  Detection of Atrial Fibrillation Using PPG From Smartphone Cameras

  NCT07779213· Source

• Recruiting

  A Study to Evaluate Efficacy and Safety of MK-8690 in Participants With Moderately to Severely Active Ulcerative Colitis (MK-8690-002)

  NCT07463183· Phase 2· Source

• Recruiting

  Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

  NCT07296484· Phase 2· Source

• Recruiting

  Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations

  NCT07143669· Source

• Recruiting

  Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM)

  NCT06837181· Source

• Recruiting

  Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

  NCT06750731· Source

• Recruiting

  Tulane iPredict, Prevent Study to Evaluate the Progression of Atrial Myopathy.

  NCT04703166· Source

• Enrolling by invitation

  Pressure-enabled Retrograde Occlusive Therapy With Embolization for Control of Thyroid Disease (PROTECT Registry): A Multicenter Registry

  NCT06868459· Source

• Recruiting

  A Study to Assess Adverse Events and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Adult Participants With Glaucoma

  NCT06822738· Phase 3· Source

• Active, not recruiting

  Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

  NCT06846541· Phase 3· Source

• Active, not recruiting

  A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD

  NCT06713239· Source

• Active, not recruiting

  Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

  NCT06632327· Phase 3· Source

• Recruiting

  Community Health Workers And MHealth to ImProve Viral Suppression Plus (CHAMPS+)

  NCT06472206· Source

• Recruiting

  A Research Study to Advance the CF Therapeutics Pipeline for People Without Modulators

  NCT06504589· Source

• Active, not recruiting

  A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

  NCT06095128· Phase 4· Source

• Active, not recruiting

  A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease

  NCT06045754· Phase 4· Source

• Recruiting

  Blood Pressure Lowering Strategies to Eliminate Hypertension Disparities (BLESSED)

  NCT06133322· Source

• Active, not recruiting

  Lupus Education Alliance Program

  NCT05243875· Source

• Active, not recruiting

  A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)

  NCT06052059· Phase 3· Source

• Active, not recruiting

  Church-based Health Intervention to Eliminate Racial Inequalities in Cardiovascular Health

  NCT06065098· Source

• Active, not recruiting

  Real World Registry for Use of the Ion Endoluminal System

  NCT06004440· Source

• Active, not recruiting

  Strength and Muscle Related Outcomes for Nutrition and Lung Function in CF

  NCT05639556· Source

• Active, not recruiting

  A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation

  NCT05757869· Phase 3· Source

• Recruiting

  A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

  NCT05650632· Phase 1· Source

• Recruiting

  Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention

  NCT05723653· Source

• Active, not recruiting

  Emicizumab in Patients With Acquired Hemophilia A

  NCT05345197· Phase 2· Source

• Active, not recruiting

  A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)

  NCT05500222· Phase 3· Source

• Active, not recruiting

  Doxycycline for Emphysema in People Living With HIV (The DEPTH Trial)

  NCT05382208· Phase 2· Source

• Active, not recruiting

  A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets

  NCT05308654· Phase 1· Source

• Active, not recruiting

  A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer

  NCT05353257· Phase 3· Source

• Active, not recruiting

  Prospective Study of Pregnancy in Women With Cystic Fibrosis

  NCT04828382· Source

• Active, not recruiting

  A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.

  NCT04680052· Phase 3· Source

• Recruiting

  Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

  NCT04269902· Phase 3· Source

• Active, not recruiting

  A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

  NCT04586231· Phase 3· Source

• Active, not recruiting

  Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

  NCT04513717· Phase 3· Source

• Active, not recruiting

  The Allergen Reduction and Child Health Study (ARCHS)

  NCT04331353· Source

• Active, not recruiting

  Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

  NCT04071223· Phase 2· Source

• Active, not recruiting

  NCI COVID-19 in Cancer Patients, NCCAPS Study

  NCT04387656· Source

• Active, not recruiting

  Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial

  NCT04134260· Phase 3· Source

• Active, not recruiting

  Promote Weight Loss in Obese Peripheral Artery Disease (PAD) Patients to Prevent Mobility Loss

  NCT04228978· Source

• Active, not recruiting

  Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer

  NCT03976843· Phase 2· Source

• Active, not recruiting

  Implementation of Multifaceted Patient-Centered Treatment Strategies for Intensive Blood Pressure Control in Minimize Cognitive Decline

  NCT04797403· Source

• Active, not recruiting

  Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

  NCT03932201· Source

• Recruiting

  Stroke Thrombectomy and Aneurysm Registry

  NCT04994756· Source

• Recruiting

  Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

  NCT03937635· Phase 3· Source

• Active, not recruiting

  S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

  NCT04071457· Phase 3· Source

• Active, not recruiting

  Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)

  NCT03924895· Phase 3· Source

• Active, not recruiting

  A Study of TNB-383B in Participants With Relapsed or Refractory Multiple Myeloma

  NCT03933735· Phase 1/2· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• HIV3 recruiting
• Atrial fibrillation2 recruiting
• Cystic fibrosis2 recruiting
• Multiple myeloma2 recruiting
• Ulcerative colitis2 recruiting
• Chronic myeloid leukaemia1 recruiting
• Crohn's disease1 recruiting
• Glaucoma1 recruiting
• High blood pressure1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Osteoporosis1 recruiting
• Stroke1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06586112· Phase 3· Source

• Completed

  A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

  NCT06016088· Phase 1/2· Source

• Completed

  Building Engagement Using Financial Incentives Trial - Colorectal Cancer Screening

  NCT06124131· Source

• Completed

  Study of TTI-101 in Participants With Idiopathic Pulmonary Fibrosis

  NCT05671835· Phase 2· Source

• Completed

  Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis

  NCT05199337· Phase 1/2· Source

• Completed

  Understanding the Long-term Impact of COVID-19 in Adults (RECOVER)

  NCT05172024· Source

• Completed

  A Study to Learn About the Study Medicine (Elranatamab) in Participants With Multiple Myeloma That Has Come Back After Responding to Treatment or Has Not Responded to Treatment

  NCT05014412· Phase 2· Source

• Completed

  Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)

  NCT04091386· Source

• Terminated

  To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

  NCT04551053· Phase 3· Source

• Terminated

  To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

  NCT04551066· Phase 3· Source

• Completed

  Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial

  NCT04300920· Phase 3· Source

• Completed

  Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

  NCT04396860· Phase 2/3· Source

• Terminated

  Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

  NCT03926624· Phase 3· Source

• Completed

  CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

  NCT03934840· Phase 2· Source

• Completed

  Long-term Safety and Efficacy Extension Trial of Bimatoprost SR

  NCT03891446· Phase 3· Source

• Completed

  Evaluation of the Duration of Effect of Bimatoprost SR in Participants With Open-Angle Glaucoma or Ocular Hypertension

  NCT03850782· Phase 3· Source

• Completed

  Registry of Subjects With Drug Resistant Epilepsy and Treated With the VNS Therapy System.

  NCT03529045· Source

• Completed

  An Investigational Immunotherapy Study of Nivolumab in Combination With Rucaparib, Docetaxel, or Enzalutamide in Metastatic Castration-resistant Prostate Cancer

  NCT03338790· Phase 2· Source

• Completed

  Prevention and Treatment Continuum for Youth at HIV Risk, Acutely Infected and With Established HIV Infection

  NCT03205696· Source

• Completed

  Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer

  NCT03098836· Phase 2· Source

• Terminated

  Long-term Safety and Efficacy Study and Dose-Escalation Substudy of PF 06838435 in Individuals With Hemophilia B

  NCT03307980· Phase 2· Source

• Completed

  A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD)

  NCT02815891· Source

• Completed

  Whole-Brain Radiation Therapy With or Without Hippocampal Avoidance in Limited Stage or Extensive Stage Small Cell Lung Cancer

  NCT02635009· Phase 2/3· Source

• Completed

  Low-Dose or High-Dose Lenalidomide in Treating Younger Patients With Recurrent, Refractory, or Progressive Pilocytic Astrocytoma or Optic Pathway Glioma

  NCT01553149· Phase 2· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

  NCT02883049· Phase 3· Source

• Completed

  Assessing Compliance With Mercaptopurine Treatment in Younger Patients With Acute Lymphoblastic Leukemia in First Remission

  NCT01503632· Phase 3· Source

• Completed

  Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

  NCT01371981· Phase 3· Source

• Completed

  Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

  NCT01231906· Phase 3· Source

• Completed

  Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma

  NCT01190930· Phase 3· Source

• Completed

  Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma

  NCT01096368· Phase 3· Source

• Completed

  Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by Surgery

  NCT01013649· Phase 3· Source

• Completed

  Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

  NCT00980460· Phase 3· Source

• Completed

  Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor

  NCT00945009· Phase 3· Source

• Completed

  Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

  NCT00653068· Phase 3· Source

• Completed

  Tamoxifen Citrate or Letrozole With or Without Bevacizumab in Treating Women With Stage IIIB or Stage IV Breast Cancer

  NCT00601900· Phase 3· Source

• Completed

  Combination Chemotherapy With or Without Lestaurtinib in Treating Younger Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

  NCT00557193· Phase 3· Source

• Completed

  Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

  NCT00336024· Phase 3· Source

• Completed

  Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

  NCT00324805· Phase 3· Source

• Completed

  Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms' Tumor

  NCT00379340· Phase 3· Source

• Completed

  Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

  NCT00408005· Phase 3· Source

• Completed

  Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor

  NCT00352534· Phase 3· Source

• Completed

  Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

  NCT00107198· Phase 2· Source

• Recruiting

  Pompe Disease Registry Protocol

  NCT00231400· Source

• Completed

  Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

  NCT00085735· Phase 3· Source

• Recruiting

  Fabry Disease Registry & Pregnancy Sub-registry

  NCT00196742· Source

• Recruiting

  International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry

  NCT00358943· Source

Trial sites

• Tulane University1 trial
• Duplicate_Tulane University /ID# 2403271 trial
• Tulane University45 trials
• Tulane University School of Medicine61 trials
• Tulane University School of Medicine-Gastroenterology and Hepatology (Site 0154)1 trial
• Tulane University School of Medicine-Gastroenterology and Hepatology (Site 1073)1 trial
• Tulane University School of Medicine /ID# 2376321 trial
• Tulane University School of Medicine /ID# 2423221 trial
• Tulane University School of Medicine /ID# 2448541 trial
• Tulane University School of Medicine /ID# 2512041 trial
• Tulane University School of Medicine /ID# 2774861 trial
• Tulane University School of Medicine (Site 0088)1 trial
• Tulane University School of Medicine (Site 0098)1 trial
• Tulane University School of Medicine- Site Number : 8400013 trials

Conditions

Diseases this institution publishes on or runs trials for.

• HIV128 works · 5 trials
• Atrial fibrillation73 works · 3 trials
• Idiopathic pulmonary fibrosis11 works · 3 trials
• Haemophilia9 works · 4 trials
• High blood pressure4 works · 6 trials
• ANCA-associated vasculitis3 works · 0 trials